|
|
||||||||
Clinical and Research Reports |
Received January 21, 2000; revised May 8, 2000; accepted May 12, 2000. From the Department of Neurology, Alzheimer Disease Research Center, and Department of Psychiatry and Biobehavioral Sciences, UCLA School of Medicine, Los Angeles, California. Address correspondence to Dr. Cummings, Reed Neurological Research Center, UCLA School of Medicine, 710 Westwood Plaza, Los Angeles, CA 90095-1769.
Using a retrospective data analysis, the authors investigated the relationships between instrumental activities of daily living (IADLs) and neuropsychiatric symptoms, cognitive impairment, and medical illness burden in patients with Alzheimer's disease (AD). One hundred forty-three patients fulfilling the clinical criteria for probable or possible AD in an outpatient clinic were assessed for IADLs, neuropsychiatric symptoms, cognitive impairment, and medical illness burden with the Functional Activities Questionnaire (FAQ), Neuropsychiatric Inventory (NPI), Mini-Mental State Exam (MMSE), and Cumulative Illness Rating ScaleGeriatric (CIRS-G). Both MMSE and NPI scores related significantly to IADLs as measured by the FAQ. Several psychiatric symptoms were correlated significantly with IADLs. FAQ scores had no correlation with CIRS-G. Neuropsychiatric findings also were associated significantly with MMSE and had a weak correlation with CIRS-G scores. IADLs changed with cognition and neuropsychiatric disturbances in AD. Medical illness burden had little influence on functional status and a limited impact on neuropsychiatric symptoms.
Key Words: Activities of Daily Living Alzheimer's Disease Comorbidity
This article has been cited by other articles:
![]() |
E. Mioshi, C. M. Kipps, K. Dawson, J. Mitchell, A. Graham, and J. R. Hodges Activities of daily living in frontotemporal dementia and Alzheimer disease Neurology, June 12, 2007; 68(24): 2077 - 2084. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. L. Cummings, E. Schneider, P. N. Tariot, S. M. Graham, and for the Memantine MEM-MD-02 Study Group Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. Neurology, July 11, 2006; 67(1): 57 - 63. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. L. Cidboy Significance of behavioural pathology on functional performance in individuals with Alzeimer's disease and related dementials American Journal of Alzheimer's Disease and Other Dementias, September 1, 2004; 19(5): 279 - 289. [Abstract] [PDF] |
||||
![]() |
M. M. Swanberg, R. E. Tractenberg, R. Mohs, L. J. Thal, and J. L. Cummings Executive Dysfunction in Alzheimer Disease Arch Neurol, April 1, 2004; 61(4): 556 - 560. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. L. Cummings, L. Schneider, P. N. Tariot, P. R. Kershaw, and W. Yuan Reduction of Behavioral Disturbances and Caregiver Distress by Galantamine in Patients With Alzheimer's Disease Am J Psychiatry, March 1, 2004; 161(3): 532 - 538. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. A. Boyle, P. F. Malloy, S. Salloway, D. A. Cahn-Weiner, R. Cohen, and J. L. Cummings Executive Dysfunction and Apathy Predict Functional Impairment in Alzheimer Disease Am J Geriatr Psychiatry, April 1, 2003; 11(2): 214 - 221. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. J. Foley, D. B. Brock, and D. J. Lanska Trends in dementia mortality from two National Mortality Followback Surveys Neurology, February 25, 2003; 60(4): 709 - 711. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ALL ISSUES | SEARCH | TABLE OF CONTENTS |